Biocon Limited and its European partner Zentiva have achieved a major milestone with EU approval for their Liraglutide formulation. This generic version of Victoza® (for Type-2 Diabetes) and Saxenda® (for weight management) has been authorized through the Decentralized Procedure (DCP).
In the exchange filing, the company shared, “The Company and it European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza® to treat Type-2 Diabetes and Saxenda® used in the treatment of weight management.”
This approval highlights the companies’ commitment to providing affordable treatment options for diabetes and weight management across the European Union.
